R&D is one of the largest and least standardized spend categories in a pharmaceutical company’s budget — spanning CROs, lab services, clinical trial technology, and increasingly, real-world evidence (RWE). Yet many procurement organizations still manage it as a collection of ad hoc purchases rather than a coherent pharma R&D category strategy. As RWE spend grows, treating it as its own category — rather than folding it into generic “clinical services” — is becoming a competitive necessity, not a nice-to-have.
What Pharma R&D Category Strategy Actually Means
A Pharma case study can show how a category strategy is a deliberate plan for how an organization sources a defined type of spend: which suppliers to use, how to structure contracts, what quality and risk criteria matter, and how the category should evolve over time. For R&D specifically, this is complicated by the fact that spend decisions are often made by scientists and clinical operations staff who aren’t thinking in procurement terms — which means category strategy has to work with scientific decision-making, not around it.
Why RWE Is Becoming Its Own Sourcing Category
Real-world evidence — data on how a drug performs outside controlled clinical trials — has moved from a nice-to-have for post-market studies to a requirement woven throughout the product lifecycle: supporting regulatory submissions, informing payer negotiations, and increasingly shaping label expansion strategy. That shift means RWE spend has grown fast enough that it now warrants its own category management, rather than being lumped in with general clinical or market access spend.
RWE spend generally breaks into three types, and each needs different sourcing criteria:
- Data licensing (claims databases, EHR data networks, registries) — evaluated primarily on data provenance, coverage, and refresh frequency.
- Study execution (observational studies, chart reviews, patient registries) — evaluated on methodological rigor and regulatory acceptability of the resulting evidence.
- Analytics and RWE platforms (tools for turning raw real-world data into usable evidence) — evaluated on validation transparency and integration with existing data infrastructure.
Treating these as one undifferentiated rwe pharma “RWE vendor” bucket is a common mistake — the supplier evaluation criteria for a data licensor and a study execution partner have almost nothing in common.
Building an R&D Category Strategy That Includes RWE
Segment spend before setting strategy. Map current and planned RWE spend across the three types above, and against therapeutic areas and product lifecycle stages, before deciding on a sourcing approach.
Set supplier evaluation criteria specific to RWE. Beyond standard vendor criteria (cost, reliability), RWE suppliers should be assessed on data governance practices, regulatory track record (has data or evidence from this supplier been accepted by FDA or other regulators before), and methodological transparency.
Establish a governance model that includes scientific stakeholders. Because RWE decisions carry regulatory and scientific risk, procurement can’t own this category alone — governance needs joint sign-off from medical affairs, regulatory, and market access, with procurement providing commercial and contracting discipline.
Case Study Snapshot: Category Strategy in Action
(Illustrative composite scenario, not a specific named client — included to show what this looks like in practice, not as a verified case result.)
A Pharma R&D category strategy example: A mid-sized specialty pharma company had been sourcing RWE data and study execution through the same vendor management process as general clinical spend, with no differentiated evaluation criteria. After segmenting RWE spend into the three categories above and setting supplier-specific criteria, the company consolidated its data-licensing relationships around two providers with the strongest regulatory track record, while keeping study execution sourcing more flexible and therapeutic-area-specific. The result was faster supplier onboarding for future studies and clearer internal accountability for evidence quality — the kind of operational improvement that’s common when a generic category gets broken into its real sub-components.
Common Pitfalls
- Managing RWE as a subset of “clinical services” instead of its own category, which obscures spend visibility and blurs supplier accountability.
- Letting scientific teams source independently of procurement, which leads to inconsistent contract terms and duplicated vendor relationships across therapeutic areas.
- Underweighting regulatory track record in vendor selection, which can create expensive problems later if evidence generated doesn’t hold up to regulatory scrutiny.
The Bottom Line
RWE has outgrown its place as a line item inside general R&D or clinical spend. Companies building a real pharma R&D category strategy are starting to treat it as a distinct category with its own segmentation, supplier criteria, and governance — and the ones that do tend to see faster sourcing cycles and fewer evidence-quality surprises down the line.
FAQs / Q&A
Q1. What’s the difference between R&D category strategy and general procurement strategy?
R&D category strategy has to account for scientific and regulatory decision-making that sits outside traditional procurement authority, which means it typically requires closer collaboration with clinical, medical affairs, and regulatory teams than most other spend categories.
Q2. Why should RWE be its own procurement category instead of part of clinical spend?
RWE spend has distinct supplier evaluation needs (data provenance, regulatory acceptability, methodological rigor) that don’t map well onto generic clinical services criteria, and treating it separately improves both spend visibility and supplier accountability.
Q3. Who should own RWE sourcing decisions — procurement or the scientific teams?
Neither should own it alone. The strongest governance models give scientific and regulatory stakeholders authority over supplier and methodology fit, while procurement drives commercial terms, contracting, and ongoing supplier management.
Q4. What should we look for when evaluating an RWE data or analytics vendor?
Beyond standard commercial criteria, prioritize data provenance and coverage, a track record of the vendor’s data or evidence being accepted by regulators, and transparency in their methodology.
Q5. How is RWE sourcing likely to change over the next few years?
As RWE plays a larger role in regulatory submissions and payer negotiations, expect more pharma companies to formalize it as a distinct sourcing category with dedicated governance, rather than managing it informally within broader clinical spend.
